Sergio Quezada is a Professor of Cancer Immunology and Immunotherapy at University College London Cancer Institute and Chief Scientific Officer of Achilles Therapeutics. He earned his undergraduate degree in biochemistry from the P. Universidad Católica de Chile and a PhD from Dartmouth Medical School in the US. In 2004, he joined the laboratory of the Nobel Laureate Prof James Allison at MSKCC, where he unveiled mechanisms underpinning the anti-tumor activity of anti-CTLA-4 antibodies.

His work at UCL focuses on cancer immunology, tumor microenvironment, regulatory T cells and immune checkpoint blockade. His team’s research unveiled the critical role of Fc receptors and the tumor microenvironment in the mechanism of action of anti-CTLA-4 antibodies, and he is an inventor of several key patents supporting the clinical development of antibodies targeting immune checkpoints including VISTA, ICOS and CD25. In the last few years, Dr. Quezada and his team co-led the development of a first-in-class Treg-depleting anti-human CD25 antibody acquired by Roche in 2018 and is currently in clinical evaluation against solid cancers.

In addition to immune regulation, Dr. Quezada’s research also aims to characterize and interrogate immune reactivity and function within the microenvironment of different human cancers, helping identify mechanisms of response and resistance to immunotherapy. His work in this area led to the creation of a spin-off company, Achilles Therapeutics, a clinical stage company delivering personalized T cell therapies against cancer. In April 2020, Dr. Quezada stepped in as Chief Scientific Officer of Achilles to lead the current and future scientific direction of Achilles.

Dr. Quezada was a recipient of Dartmouth’s John W. Strohbern Medal for excellence in biomedical research, the Cancer Research Institute new investigator award, a CRUK Career Development Fellowship and a CRUK Senior Cancer Research Fellowship.